Biocon Pledges To Cut Insulin Prices
India’s Biocon has pledged to cut the price of insulin to 10 cents per day in low- and middle-income nations
Executive Summary
India’s Biocon has promised to cut by 50% the cost of recombinant human insulin to 10 cents a day in low- and middle-income nations to help make the life-saving medication “universally accessible.”
You may also be interested in...
Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'
Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.
Biocon Insulin Aspart US Opportunity: 'Not Completely Lost But Not The Best Situation'
Biocon may not be able to make it to the current contracting cycle in the US for its Viatris-partnered biosimilar aspart, but all is not lost, the management indicates. The Indian firm is also buoyant about the prospects of taking its franchise of potentially interchangeable recombinant human insulin to the US.
Biocon And International Diabetes Federation Promote Insulin Access
Biocon Biologics has become the first biosimilar insulins company to partner with the International Diabetes Federation to help increase affordable access to insulin worldwide. The partnership was sealed at the start of centenary celebrations of the discovery of insulin.